Reference
Peptide library
Chemical identity and regulatory status, traced to primary records. Each compound also has an evidence file of classified studies — not an effectiveness score.
32 of 32 compounds
| Compound | Class | Formula | CAS | US regulatory status | Evidence file |
|---|---|---|---|---|---|
| BPC-157Pentadecapeptide BPC 157, PL-14736 | Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC | C62H98N16O22 | 137525-51-0 | Unapproved | 9 |
| TB-500Thymosin beta-4 fragment (LKKTETQ), Ac-LKKTETQ-OH | Synthetic acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4 (residues 17–23) | C38H68N10O14 | 885340-08-9 | Unapproved | 6 |
| SemaglutideOzempic, Wegovy | GLP-1 receptor agonist (acylated GLP-1 analogue) | C187H291N45O59 | 910463-68-2 | Approved | 4 |
| TirzepatideMounjaro, Zepbound | Dual GIP and GLP-1 receptor agonist | C225H348N48O68 | 2023788-19-2 | Approved | 3 |
| IpamorelinNNC 26-0161, Ipamorelin acetate | Growth hormone secretagogue | C38H49N9O5 | 170851-70-4 | Category 2 | 5 |
| CJC-1295CJC-1295 DAC, DAC:GRF | Growth hormone-releasing hormone (GHRH) analogue | With DAC: C165H269N47O46 | With DAC: 446262-90-4 | Unapproved | 5 |
| SermorelinGeref, GRF(1-29)NH2 | GHRH analogue — human GHRH (1-29) amide | C149H246N44O42S | 86168-78-7 | Discontinued | 3 |
| GHK-CuCopper tripeptide-1, Prezatide copper | Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine | C14H23CuN6O4+ (prezatide copper, PubChem CID 71587328) | 89030-95-5 (copper complex) | Unapproved | 4 |
| Thymosin alpha-1Thymalfasin, Tα1 | Synthetic 28-residue N-acetylated peptide corresponding to the N-terminal fragment of prothymosin alpha | C129H215N33O55 | 62304-98-7 | Unapproved | 3 |
| Melanotan IIMT-II, MTII | Cyclic heptapeptide | C50H69N15O9 | 121062-08-6 | Unapproved | 3 |
| BremelanotidePT-141, Vyleesi | Cyclic heptapeptide melanocortin receptor agonist | C50H68N14O10 | 189691-06-3 | Approved | 2 |
| TesamorelinEgrifta, TH9507 | Stabilised GHRH analogue — human GHRH(1-44) amide, N-terminally acylated | C221H366N72O67S | 218949-48-5 | Approved | 3 |
| SelankTP-7, Selank acetate | Synthetic heptapeptide | C33H57N11O9 | 129954-34-3 | Unapproved | 2 |
| EpitalonEpithalon, AEDG peptide | Synthetic tetrapeptide | C14H22N4O9 | 307297-39-8 | Unapproved | 4 |
| AOD-9604AOD9604, Tyr-hGH 177-191 | Synthetic hexadecapeptide corresponding to the C-terminal fragment of human growth hormone with an N-terminal tyrosine | C78H123N23O23S2 | 221231-10-3 | Unapproved | 3 |
| KPVLys-Pro-Val, α-MSH (11-13) | Tripeptide corresponding to the C-terminal sequence of α-melanocyte-stimulating hormone | C16H30N4O4 | 67727-97-3 | Unapproved | 4 |
| MOTS-cMOTS-C, Mitochondrial ORF of the 12S rRNA type-c | 16-residue peptide encoded by a short open reading frame in mitochondrial 12S rRNA | C101H152N28O22S2 | 1627580-64-6 | Unapproved | 3 |
| SemaxMEHFPGP, ACTH(4-10) analogue | Synthetic heptapeptide analogue of ACTH(4-10) with a C-terminal Pro-Gly-Pro extension | C37H51N9O10S | 80714-61-0 | Unapproved | 3 |
| EmideltideDSIP, Delta sleep-inducing peptide | Synthetic nonapeptide (delta sleep-inducing peptide) | C35H48N10O15 | 62568-57-4 | Unapproved | 3 |
| RetatrutideLY3437943, LY-3437943 | Investigational triple agonist of GIP, GLP-1 and glucagon receptors | Unknown | 2381089-83-2 | Investigational | 2 |
| LiraglutideVictoza, Saxenda | GLP-1 receptor agonist (acylated GLP-1 analogue) | C172H265N43O51 | 204656-20-2 | Approved | 0 |
| ExenatideByetta, Bydureon | GLP-1 receptor agonist (synthetic exendin-4) | C184H282N50O60S | 141758-74-9 | Approved | 0 |
| PramlintideSymlin, AC-137 | Amylin analogue | C171H267N51O53S2 | 151126-32-8 | Discontinued | 0 |
| Cagrilintide | Investigational long-acting acylated amylin analogue | C194H312N54O59S2 | 1415456-99-3 | Investigational | 0 |
| SetmelanotideImcivree, RM-493 | Cyclic octapeptide melanocortin-4 (MC4) receptor agonist | C49H68N18O9S2 | 920014-72-8 | Approved | 0 |
| AfamelanotideScenesse, Melanotan I | Linear 13-residue α-MSH analogue | C78H111N21O19 | 75921-69-6 | Approved | 0 |
| ElamipretideForzinity, SS-31 | Mitochondria-targeted tetrapeptide, described in FDA labelling as a mitochondrial cardiolipin binder | C32H49N9O5 | 736992-21-5 | Approved | 0 |
| Thymosin beta-4Timbetasin, Thymosin β4 | 43-residue N-terminally acetylated peptide | C212H350N56O78S | 77591-33-4 | Unapproved | 0 |
| Cathelicidin LL-37LL-37, CAP18 | 37-residue peptide derived from human cathelicidin | C205H340N60O53 | 154947-66-7 | Unapproved | 0 |
| Kisspeptin-10KP-10, Metastin (45-54) | Decapeptide corresponding to the C-terminal region of human kisspeptin (metastin residues 45–54) | C63H83N17O14 | 374675-21-5 | Category 2 | 0 |
| GHRP-2Pralmorelin, KP-102 | Growth hormone secretagogue | C45H55N9O6 | 158861-67-7 | Category 2 | 0 |
| HexarelinExamorelin, EP-23905 | Growth hormone secretagogue | C47H58N12O6 | 140703-51-1 | Unapproved | 0 |
These records describe what a compound is and how it is classified. They do not describe effects, uses, protocols or outcomes, and regulatory status is not a safety assessment. Where authoritative sources disagree — and for several of these compounds they do — the disagreement is recorded on the compound page rather than resolved silently.